Patient characteristics
| Characteristic . | FCR study (n = 177) . | Subsequent protocols (n = 127) . | ||
|---|---|---|---|---|
| Median age, y (range) | UM | 58 (24-82) | UM | 58 (36-82) |
| M | 58 (35-76) | M | 57 (27-76) | |
| Male sex, n (%) | UM | 80 (76) | UM | 68 (78) |
| M | 56 (78) | M | 26 (65) | |
| More than 2 years from diagnosis, n (%) | UM | 50 (48) | UM | 35 (40) |
| M | 42 (58) | M | 19 (48) | |
| Rai stages 3-4, n (%) | UM | 36 (34) | UM | 23 (26) |
| M | 28 (39) | M | 13 (33) | |
| White cell count ≥ 150 × 109/L, n (%) | UM | 25 (24)* | UM | 22 (25) |
| M | 9 (13)* | M | 6 (15) | |
| β2m greater than or equal to 2× upper limit normal, n (%) | UM | 51 (49)† | UM | 37 (43) |
| M | 22 (31)† | M | 13 (33) | |
| Abnormal karyotype, n (%) | UM | 24 (32)‡ | UM | 30 (42) |
| M | 7 (15)‡ | M | 9 (30) | |
| Missing data | 54 patients | Missing data | 25 patients | |
| FISH deletion of 11q or 17p, n (%) | UM | — | UM | 30 (41)§ |
| M | — | M | 2 (7)§ | |
| Missing data | 177 patients | Missing data | 23 patients | |
| Complete response, n (%) | FCR, UM | 77 (73)¶ | All reg, UM | 62 (71)‖ |
| FCR, M | 60 (83)¶ | All reg, M | 31 (78)‖ | |
| — | — | FCR3, UM | 25 (66)# | |
| — | — | FCR3, M | 14 (78)# | |
| — | — | FCMR, UM | 11 (79)** | |
| — | — | FCMR, M | 10 (100)** | |
| — | — | FCR + GM, UM | 14 (82)†† | |
| — | — | FCR + GM, M | 2 (50)†† | |
| — | — | CFAR, UM | 12 (67)‡‡ | |
| — | — | CFAR, M | 5 (63)‡‡ | |
| Characteristic . | FCR study (n = 177) . | Subsequent protocols (n = 127) . | ||
|---|---|---|---|---|
| Median age, y (range) | UM | 58 (24-82) | UM | 58 (36-82) |
| M | 58 (35-76) | M | 57 (27-76) | |
| Male sex, n (%) | UM | 80 (76) | UM | 68 (78) |
| M | 56 (78) | M | 26 (65) | |
| More than 2 years from diagnosis, n (%) | UM | 50 (48) | UM | 35 (40) |
| M | 42 (58) | M | 19 (48) | |
| Rai stages 3-4, n (%) | UM | 36 (34) | UM | 23 (26) |
| M | 28 (39) | M | 13 (33) | |
| White cell count ≥ 150 × 109/L, n (%) | UM | 25 (24)* | UM | 22 (25) |
| M | 9 (13)* | M | 6 (15) | |
| β2m greater than or equal to 2× upper limit normal, n (%) | UM | 51 (49)† | UM | 37 (43) |
| M | 22 (31)† | M | 13 (33) | |
| Abnormal karyotype, n (%) | UM | 24 (32)‡ | UM | 30 (42) |
| M | 7 (15)‡ | M | 9 (30) | |
| Missing data | 54 patients | Missing data | 25 patients | |
| FISH deletion of 11q or 17p, n (%) | UM | — | UM | 30 (41)§ |
| M | — | M | 2 (7)§ | |
| Missing data | 177 patients | Missing data | 23 patients | |
| Complete response, n (%) | FCR, UM | 77 (73)¶ | All reg, UM | 62 (71)‖ |
| FCR, M | 60 (83)¶ | All reg, M | 31 (78)‖ | |
| — | — | FCR3, UM | 25 (66)# | |
| — | — | FCR3, M | 14 (78)# | |
| — | — | FCMR, UM | 11 (79)** | |
| — | — | FCMR, M | 10 (100)** | |
| — | — | FCR + GM, UM | 14 (82)†† | |
| — | — | FCR + GM, M | 2 (50)†† | |
| — | — | CFAR, UM | 12 (67)‡‡ | |
| — | — | CFAR, M | 5 (63)‡‡ | |
Unless specified otherwise, comparisons between categories were not statistically significant.
FCR indicates fludarabine, cyclophosphamide, and rituximab; UM, unmutated IgVH; M, mutated IgVH; β2m, β2-microglobulin; FISH, fluorescence in situ hybridization; FCR3, FCR with thrice-weekly rituximab in first week of each cycle; FCMR, FCR and mitoxantrone; FCR + GM, FCR and granulocyte macrophage colony-stimulating factor; and CFAR, FCR and alemtuzumab.
P = .08.
P = .02.
P = .05.
P < .001.
P = .12.
P = .46.
P = .54.
P = .24.
P = .23.
P = 1.00.